Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Terapia génica y Hepatología >
Inmunología terapia génica >
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista >
|Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors|
|Authors: ||Sangro, B. (Bruno)|
Mazzolini, G. (Guillermo)
Ruiz, J. (Juan)
Herraiz-Bayod, M.J. (Maite J.)
Quiroga, J. (Jorge)
Herrero, J.I. (José Ignacio)
Benito, A. (Alberto)
Larrache, J. (Javier)
Pueyo, J. (Jesús)
Subtil, J.C. (José Carlos)
Olagüe, C. (Cristina)
Sola, J. (Josu)
Sadaba, B. (Belén)
Lacasa, C. (Carlos)
Melero, I. (Ignacio)
Qian, C. (Cheng)
Prieto, J. (Jesús)
|Keywords: ||Digestive System Neoplasms/therapy|
|Issue Date: ||2004|
|Publisher: ||American Society of Clinical Oncology|
|Publisher version: ||http://jco.ascopubs.org/content/22/8/1389|
|Citation: ||Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004 Apr 15;22(8):1389-1397.|
To evaluate the feasibility and safety of intratumoral injection of an adenoviral vector encoding human interleukin-12 genes (Ad.IL-12) and secondarily, its biologic effect for the treatment of advanced digestive tumors.
PATIENTS AND METHODS:
Ad.IL-12 was administered in doses ranging from 2.5 x 10(10) to 3 x 10(12) viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients were thoroughly assessed for toxicity, and antitumor response was evaluated by imaging techniques, tumor biopsy, and hypersensitivity skin tests. Patients with stable disease and no serious adverse reactions were allowed to receive up to 3 monthly doses of Ad.IL-12.
Twenty-one patients (nine with primary liver, five with colorectal, and seven with pancreatic cancers) received a total of 44 injections. Ad.IL-12 was well tolerated, and dose-limiting toxicity was not reached. Frequent but transient adverse reactions, including fever, malaise, sweating, and lymphopenia, seemed to be related to vector injection rather than to transgene expression. No cumulative toxicity was observed. In four of 10 assessable patients, a significant increase in tumor infiltration by effector immune cells was apparent. A partial objective remission of the injected tumor mass was observed in a patient with hepatocellular carcinoma. Stable disease was observed in 29% of patients, mainly those with primary liver cancer.
Intratumoral injection of up to 3 x 10(12) viral particles of Ad.IL-12 to patients with advanced digestive malignancies is a feasible and well-tolerated procedure that exerts only mild antitumor effects.
|Permanent link: ||http://hdl.handle.net/10171/21791|
|Appears in Collections:||DA - Medicina - Medicina Interna - Artículos de revista|
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista
|Files in This Item:|
There are no files associated with this item.
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.